Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 12/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | DHFR | P00374 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR6 | P46095 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2166247 | 0.88 | DCPS (0.61) | DCPSCYP2D6DHFRKDM4EALDH1A1 | |
| SCHEMBL2167452 | 0.82 | DCPS (0.59) | DCPSCYP2D6DHFR | |
| SCHEMBL2166641 | 0.81 | DCPS (0.46) | DCPSCYP2D6DHFRKDM4EALDH1A1 | |
| SCHEMBL2166006 | 0.81 | KDM4E (0.53) | DCPSDHFRKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2165238 | 0.79 | KMT2A (0.51) | DCPSCYP2D6DHFRKDM4EALDH1A1 | |
| SCHEMBL2165395 | 0.79 | DRD2 (0.56) | DCPSCYP2D6DHFRKDM4EALDH1A1 | |
| SCHEMBL2167390 | 0.79 | ALDH1A1 (0.64) | DCPSCYP2D6DHFRKDM4ESMN1; SMN2 | |
| SCHEMBL2166082 | 0.78 | DCPS (0.58) | DCPSDHFRKDM4EALDH1A1KMT2A | |
| SCHEMBL2165096 | 0.78 | DCPS (0.68) | DCPSCYP2D6DHFRKDM4EALDH1A1 | |
| SCHEMBL2166371 | 0.78 | DCPS (0.82) | DCPSCYP2D6DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069316-B1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2615086-A1 | 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2069316-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008016973-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYT1 | DCPS 1366/4885CYP2D6 3869/4885DHFR 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.